We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+14.58%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$865M
AUM Growth
+$9.54M
(+1.1%)
Cap. Flow
-$78.4M
Cap. Flow
% of AUM
-9.07%
Top 10 Holdings %
Top 10 Hldgs %
8.56%
Holding
892
New
315
Increased
150
Reduced
128
Closed
299
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XP
XP
|
+$7.27M |
| 2 |
Constellation Brands
STZ
|
+$7.01M |
| 3 |
Eli Lilly
LLY
|
+$6.9M |
| 4 |
Automatic Data Processing
ADP
|
+$6.79M |
| 5 |
Nu Holdings
NU
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.9M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$11.9M |
| 3 |
Microsoft
MSFT
|
+$11.8M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$11.7M |
| 5 |
Las Vegas Sands
LVS
|
+$11.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.67% |
| 2 | Healthcare | 18.49% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Industrials | 10.31% |
| 5 | Financials | 10.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Roku
ROKU
$21.5B
| $6.3M | 0.73% |
68,762
+45,171
| +191% | +$3.78M |
|
27
TechnipFMC
FTI
$27.7B
| $6.2M | 0.72% |
307,805
+247,744
| +412% | +$5.08M |
|
|
DOCU
28
DocuSign
DOCU
$10.4B
| $6.17M | 0.71% |
103,812
-118,920
| -53% | -$5.45M |
|
|
JWN
29
DELISTED
Nordstrom
JWN
| $6.13M | 0.71% |
+332,121
| New | +$5.1M |
|
30
Equitable Holdings
EQH
$13.1B
| $6.02M | 0.7% |
+180,790
| New | +$5.29M |
|
31
Alcoa
AA
$11.9B
| $5.98M | 0.69% |
175,899
+166,009
| +1,679% | +$4.49M |
|
32
West Pharmaceutical
WST
$23.7B
| $5.79M | 0.67% |
16,449
+15,125
| +1,142% | +$5.35M |
|
33
Boston Scientific
BSX
$66.8B
| $5.73M | 0.66% |
+99,136
| New | +$5.29M |
|
34
TJX Companies
TJX
$174B
| $5.71M | 0.66% |
60,885
-543
| -0.9% | -$48.7K |
|
|
SPR
35
DELISTED
Spirit AeroSystems
SPR
| $5.69M | 0.66% |
+179,182
| New | +$4.39M |
|
36
PENN Entertainment
PENN
$2.72B
| $5.54M | 0.64% |
213,019
+103,937
| +95% | +$2.41M |
|
37
Paycom
PAYC
$7.53B
| $5.54M | 0.64% |
26,791
+21,856
| +443% | +$4.62M |
|
38
Wolfspeed
WOLF
$1.24B
| $5.45M | 0.63% |
125,279
+26,953
| +27% | +$978K |
|
39
Norwegian Cruise Line
NCLH
$8.48B
| $5.28M | 0.61% |
263,606
+73,401
| +39% | +$1.18M |
|
40
Pinterest
PINS
$13.4B
| $5.26M | 0.61% |
142,040
+108,657
| +325% | +$3.42M |
|
41
Cytokinetics
CYTK
$10.6B
| $5.2M | 0.6% |
+62,229
| New | +$2.25M |
|
42
Cigna
CI
$74.5B
| $5.08M | 0.59% |
+16,964
| New | +$4.96M |
|
43
UiPath
PATH
$6.46B
| $4.88M | 0.56% |
196,571
+121,470
| +162% | +$2.37M |
|
|
WBA
44
DELISTED
Walgreens Boots Alliance
WBA
| $4.74M | 0.55% |
181,531
+76,727
| +73% | +$1.72M |
|
45
Gold Fields
GFI
$28.6B
| $4.42M | 0.51% |
305,702
+290,543
| +1,917% | +$4.02M |
|
46
Wabtec
WAB
$49.4B
| $4.38M | 0.51% |
34,515
+24,410
| +242% | +$2.76M |
|
47
Samsara
IOT
$21.2B
| $4.23M | 0.49% |
+126,586
| New | +$3.52M |
|
48
Immunovant
IMVT
$7.86B
| $4.15M | 0.48% |
98,606
+53,200
| +117% | +$1.96M |
|
49
Mastercard
MA
$503B
| $4.1M | 0.47% |
+9,615
| New | +$3.86M |
|
50
Regeneron Pharmaceuticals
REGN
$76.4B
| $4M | 0.46% |
4,557
+3,582
| +367% | +$2.95M |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Seven Eight Capital held 892 positions worth $865M, up 1.1% from $855M the previous quarter. Its ten largest holdings account for 8.6% of the portfolio.
Seven Eight Capital withdrew a net $78.4M in Q4 2023, closing 299 positions and reducing 128 holdings. Its most notable exit was Merck, an estimated $11.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Seven Eight Capital opened a new position in XP worth $8.3M.
- Seven Eight Capital's largest Q4 2023 buy was XP: 318,542 shares worth $8.3M.
- Seven Eight Capital added most to Constellation Brands in Q4 2023, an estimated $7.01M increase.
- Seven Eight Capital's biggest Q4 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $11.9M.
- Seven Eight Capital fully exited Merck in Q4 2023, selling an estimated $11.9M.
- Seven Eight Capital's ten largest holdings make up 8.6% of its $865M portfolio in Q4 2023.
- Seven Eight Capital opened 315 new positions and closed 299 in Q4 2023.
- Seven Eight Capital's portfolio value rose 1.1% quarter-over-quarter to $865M.
Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.